

Window on the Science

Diabetes is on the rise

There are almost four times as many people living with diabetes today as there were in the 1980s. Rates of diabetes have been fuelled by obesity, poor diet and inactivity, and are increasing the fastest in low and middle-income countries.

108 million

Adults with diabetes in 1980.

4.7%

Global prevalence of diabetes among adults in 1980.

Source: International Diabetes Federation Diabetes Atlas (8th edition) 2017

425 million

Adults with diabetes in 2017.

9.9%

Global prevalence of diabetes among adults in 2017.



\$327 billion

Cost of diagnosed diabetes every year in the US alone.

\$1 in \$7

Proportion of US healthcare budget spent treating diabetes and its complications.

2.3x

Healthcare costs for Americans with diabetes compared to Americans without diabetes.

Source: American Diabetes Association

A growing global health emergency

As diabetes cases increase, the costs associated with managing the condition threaten to overwhelm health systems around the world.

Kidney disease is one of the major complications of diabetes

Diabetic kidney disease can lead to kidney failure requiring either a transplant or a lifetime of dialysis.

1 in 3

Adults with newly diagnosed type 2 diabetes already have chronic kidney disease.

US\$89,000

Cost of dialysis per person per year.

7.5 years

Average life expectancy once dialysis has commenced, however, 20% of patients die within one year.

Source: US Centers for Disease Control and Prevention; US Renal Data System

PromarkerD changing lives

PromarkerD is the world's first predictive diagnostic test for diabetic kidney disease. The test searches for biomarkers in the blood - or protein 'fingerprints' - associated with the onset of the disease. PromarkerD offers patients a choice.

3

Biomarkers in the blood the **PromarkerD** test searches for.

Up to four

Years in advance that **PromarkerD** can predict the onset of clinical symptoms of diabetic kidney disease.

86%

Proportion of otherwise healthy diabetics who go on to develop chronic kidney disease within four years correctly predicted by **PromarkerD**.

21

Drugs for the treatment of diabetic kidney disease currently in clinical trials.

1

In April 2019 Janssen Pharmaceutical's drug canagliflozin was shown in clinical trials to successfully provide renal (kidney) protection - the first new kidney disease drug for nearly 20 years.

Emerging treatments further boost PromarkerD potential

The PromarkerD test is poised to become even more powerful in the coming years as drugs to treat diabetic kidney disease come to market. PromarkerD can be used as a complementary diagnostic test as these drugs become available.